Cyclophosphamide bolus therapy in refractory Crohn’s disease – patient registry

Cyclophosphamide bolus therapy in refractory Crohn’s disease – patient registry - Cyclocrohn

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009494

Enrollment

Registered

2015-10-12

Start date

2011-11-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Crohn's disease K50

Interventions

Group 1: Crohn's disease patients with cyclophosphamide bolus therapy Socialdemographic data and clinical data (e.g. Montreal classification, anamnesis, pre-medication, previous operations, CDAI, appl

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Crohn's disease patients with cyclophosphamid bolus therapy - over 18 years old

Exclusion criteria

Exclusion criteria: pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Effectiveness of cyclophosphamid bolus therapy by refractory Crohn’s disease – remission induction (CDAI = 150) at week 12 after therapy start	—

Secondary

Measure	Time frame
- Optimierung der Therapiestrategie -Effectiveness of cyclophosphamid bolus therapy by refractory Crohn’s disease – remission duration after the cyclophosphami therapy -Safety of the cyclophosphamid bolus therapy by patients with refractory Crohn’s disease (if required SAE/-AE-reporting) -Identification of a patient cohort, which can benefit from the cyclophosphamid bolus therapy - Optimisation of therapy strategy	—

Measure

Time frame

- Optimierung der Therapiestrategie -Effectiveness of cyclophosphamid bolus therapy by refractory Crohn’s disease – remission duration after the cyclophosphami therapy -Safety of the cyclophosphamid bolus therapy by patients with refractory Crohn’s disease (if required SAE/-AE-reporting) -Identification of a patient cohort, which can benefit from the cyclophosphamid bolus therapy - Optimisation of therapy strategy

—

Countries

Germany

Contacts

Public ContactJürgen Büning

Universitätsklinikum Schleswig-HolsteinMed. Klinik I

juergen.buening@uksh.de0451 500-6482 / -0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026